OxDx raises £2.6m for AI diagnostics technology
OxDX, a University of Oxford spin-off building instant pathogen tests using super-resolution microscopy and machine learning, has raised £2.6m in funding from pre-priming for its AI-powered diagnostic technology that can recognize and identify specific strains of viruses, bacteria and other pathogens in a sample in seconds.
The seed funding is co-led by IQ Capital and Ahren Innovation Capital with participation from Science Creates Ventures and will be used to expand the team and further validate the technology with development partners.
OxDX technology uses new universal labeling technology in combination with machine learning analysis in a neural network to identify specific pathogens causing infection in just seconds. The team has demonstrated the ability to identify respiratory viruses in clinical specimens and, in the case of COVID-19 and influenza viruses, to directly identify the strain. The Company aims to develop an ultra-fast analysis platform capable of rapidly adapting to many diseases via simple software updates improving the cost and access to the diagnosis of infectious diseases worldwide.
Alex Batchelor, chief executive of OxDX, said, “Our ability to take a sample from someone with an unknown infection and answer the open-ended question ‘what does she have? in a minute is a game-changer for the diagnosis and treatment of infections. We’ll start with respiratory viruses and expand from there. At the same time, we will simplify the workflow to move testing from the lab to point-of-care, which will represent a step change in the availability and cost of infectious disease diagnostics globally.
Ed Stacey, Managing Partner at IQ Capital Partners, added: “The potential of OxDX’s technology to identify diseases ‘while you wait’ and deploy tests for new pathogens with a simple software update will revolutionize diagnosis and treatment of patients. This amazing team has already accomplished so much and I can’t wait to see the impact they will have on the field of infectious disease diagnostics.
Dr. Joanna Green, Director of Ahren Innovation Capital, said, “We look forward to working with the OxDX team to unlock the full potential of their technology, operating at the intersection of machine learning and microscopy, applied to diagnosis. This type of transformative technology can have a huge positive impact on the world. »